Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + Chemo in ALK+ NSCLC after TKI failure
NCT04425135Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Xiamen University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04425135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425135.